Buy Or Sell Opportunity • May 14
Now 22% overvalued Over the last 90 days, the stock has fallen 6.1% to ₩4,695. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%. Buy Or Sell Opportunity • Apr 13
Now 20% overvalued Over the last 90 days, the stock has fallen 4.6% to ₩4,625. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 22%. New Risk • Mar 27
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 3,533% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩59.6b market cap, or US$39.4m). Buy Or Sell Opportunity • Mar 20
Now 21% overvalued Over the last 90 days, the stock has fallen 12% to ₩4,640. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%. Buy Or Sell Opportunity • Mar 05
Now 20% overvalued Over the last 90 days, the stock has fallen 12% to ₩4,630. The fair value is estimated to be ₩3,850, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 22%. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩4,370, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 26% over the past three years. Anuncio • Feb 24
Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026 Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South Korea Upcoming Dividend • Dec 22
Upcoming dividend of ₩150 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 20 April 2026. Trailing yield: 2.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%). New Risk • Nov 28
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 25% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Minor Risks Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (₩61.9b market cap, or US$42.1m). Declared Dividend • Nov 08
Dividend of ₩150 announced Dividend of ₩150 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 2.9%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 11% per year over the past 4 years and payments have been stable during that time. Anuncio • Nov 07
Jin Yang Pharmaceutical Co., Ltd. announces Annual dividend, payable on April 20, 2026 Jin Yang Pharmaceutical Co., Ltd. announced Annual dividend of KRW 150.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Anuncio • Feb 25
Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025 Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2025, at 09:00 Tokyo Standard Time. Location: auditorium, 34, sinpyeong-ro, jijeong-myeon, gangwon-do, wonju South Korea New Risk • Jan 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (70% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (5.9% increase in shares outstanding). Market cap is less than US$100m (₩89.7b market cap, or US$61.5m). Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to ₩7,850, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years. Declared Dividend • Dec 19
Dividend of ₩150 announced Shareholders will receive a dividend of ₩150. Ex-date: 27th December 2024 Payment date: 1st January 1970 Dividend yield will be 2.5%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 14% per year over the past 3 years and payments have been stable during that time. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩6,180, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 12x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 3.0% over the past three years. Reported Earnings • Nov 15
Third quarter 2024 earnings released: EPS: ₩2,008 (vs ₩363 in 3Q 2023) Third quarter 2024 results: EPS: ₩2,008 (up from ₩363 in 3Q 2023). Revenue: ₩31.6b (up 31% from 3Q 2023). Net income: ₩22.2b (up 468% from 3Q 2023). Profit margin: 70% (up from 16% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. New Risk • Aug 28
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.5% Last year net profit margin: 18% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.5% net profit margin). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩64.1b market cap, or US$48.0m). Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₩7,250, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 1.8% over the past three years. New Risk • Aug 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Market cap is less than US$100m (₩62.0b market cap, or US$45.9m). New Risk • Mar 16
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 24% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Market cap is less than US$100m (₩63.8b market cap, or US$48.0m). Upcoming Dividend • Dec 20
Upcoming dividend of ₩150 per share at 2.4% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. Trailing yield: 2.4%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%). Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ₩363 (vs ₩560 in 3Q 2022) Third quarter 2023 results: EPS: ₩363 (down from ₩560 in 3Q 2022). Revenue: ₩24.1b (up 10% from 3Q 2022). Net income: ₩3.92b (down 37% from 3Q 2022). Profit margin: 16% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • May 14
First quarter 2023 earnings released: EPS: ₩256 (vs ₩153 in 1Q 2022) First quarter 2023 results: EPS: ₩256 (up from ₩153 in 1Q 2022). Revenue: ₩22.4b (up 27% from 1Q 2022). Net income: ₩2.76b (up 61% from 1Q 2022). Profit margin: 12% (up from 9.7% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Upcoming Dividend • Dec 21
Upcoming dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 20 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Nov 13
Third quarter 2022 earnings released: EPS: ₩560 (vs ₩186 in 3Q 2021) Third quarter 2022 results: EPS: ₩560 (up from ₩186 in 3Q 2021). Revenue: ₩21.8b (up 40% from 3Q 2021). Net income: ₩6.18b (up 198% from 3Q 2021). Profit margin: 28% (up from 13% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Inaugural dividend of ₩100.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit but it is cash flow positive. This is the first dividend for Jin Yang Pharmaceutical since going public. The average dividend yield among industry peers is 0.8%. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment deteriorated over the past week After last week's 21% share price decline to ₩6,420, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 86% over the past three years. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improved over the past week After last week's 15% share price gain to ₩7,580, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 24x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years. Valuation Update With 7 Day Price Move • Jul 19
Investor sentiment improved over the past week After last week's 22% share price gain to ₩8,300, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 121% over the past three years. Is New 90 Day High Low • Feb 23
New 90-day low: ₩5,940 The company is down 20% from its price of ₩7,410 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Anuncio • Feb 17
Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021 Jin Yang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Jan 28
New 90-day low: ₩6,300 The company is down 2.0% from its price of ₩6,440 on 30 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 13% over the same period. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩100.00 Per Share Will be paid on the 13th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in April 2010. The average dividend yield among industry peers is 0.6%. Is New 90 Day High Low • Oct 26
New 90-day low: ₩6,350 The company is down 8.0% from its price of ₩6,900 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. 
